"Albuminuria" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Descriptor ID |
D000419
|
| MeSH Number(s) |
C12.777.934.734.269 C13.351.968.934.734.269 C23.888.942.750.269
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Albuminuria".
Below are MeSH descriptors whose meaning is more specific than "Albuminuria".
This graph shows the total number of publications written about "Albuminuria" by people in this website by year, and whether "Albuminuria" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 3 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 4 | 5 |
| 2010 | 3 | 3 | 6 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 2 | 4 |
| 2017 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Albuminuria" by people in Profiles.
-
Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation. BMJ. 2026 Sep 16; 394:e100574.
-
Worsening heart failure events in adults with mild-to-moderate chronic kidney disease. Am Heart J. 2026 Feb; 292:107290.
-
Impaired sensitivity to thyroid hormones is associated with albuminuria in the euthyroid population: results from NHANES. Hormones (Athens). 2024 Jun; 23(2):245-255.
-
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616.
-
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 02 06; 149(6):450-462.
-
Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. Am J Hypertens. 2023 10 13; 36(11):612-618.
-
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. 2023 08 01; 8(8):732-741.
-
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 02 13; 38(2):372-383.
-
Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 01 24; 81(3):270-282.
-
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.